. 2018 Nov 29;13(3):182–187. doi: 10.1097/ADM.0000000000000476
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
FIGURE 1.
Treatment retention by BZD classification. BZD, benzodiazepine.